๐Ÿ”ฌDeep Research

VSTM โ€” Verastem Inc ยท catalysts, narrative & risks

ยท29 sourcesVSTM forecast โ†’

Verastem Oncology (VSTM) โ€” Point-in-Time Research Summary (as of Oct 21, 2026)

Company profile: Verastem, Inc. (trading as Verastem Oncology; Nasdaq: VSTM; ISIN US92337C2035) is a Needham, Massachusetts-based development-stage biopharmaceutical company focused on RAS/MAPK pathway-driven cancers. Its portfolio includes an FDA-approved combination (avutometinib + defactinib, marketed as AVMAPKI FAKZYNJA CO-PACK) and an in-development oral KRAS G12D inhibitor, VS-7375. [24], [21], [22], [26]


Key recent catalysts (last ~1โ€“3 months)


AI-assisted research from the K3vl4r desk โ€” not personalized investment advice. More research โ†’